This profitable Netherlands-based biotech name has produced triple-digit quarterly earnings growth.

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Amylyx ...

Novartis (NYSE: NVS) is paying $1.1 billion upfront to buy Myricx Bio, a London-based biotech with its U.S. presence based in ...

Novartis AG NVS has agreed to acquire privately held U.K. biotechnology company Myricx Bio in a deal valued at up to $1.5 ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...